Search research articles
Contact Us
Filters
Showing results (161-170 of 209) with videos related to
Page
of 21
Sort By:
Nature Medicine
|
August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
European Urology
|
November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
The Oncologist
|
March 14, 2023
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Qiang Li, Alexis W Damish, Zoë Frazier, et al.
Science (New York, N.Y.)
|
October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu, Robin Mogg, Mark Ayers, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
Nature Communications
|
December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
David Liu, Philip Abbosh, Daniel Keliher, et al.
European Urology Oncology
|
November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial
Fern Anari, John O'Neill, Woonyoung Choi, et al.
The New England Journal of Medicine
|
February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 209) with videos related to
Sort By:
Page
of 21
Nature Medicine
|
August 1, 2025
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
European Urology
|
November 9, 2021
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
Laurence Albiges, Nizar M Tannir, Mauricio Burotto, et al.
The Oncologist
|
March 14, 2023
Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
Cristiane Decat Bergerot, Jasnoor Malhotra, Paulo Bergerot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 11, 2021
Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2018
<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Qiang Li, Alexis W Damish, Zoë Frazier, et al.
Science (New York, N.Y.)
|
October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu, Robin Mogg, Mark Ayers, et al.
Cancer
|
April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Robert J Motzer, David F McDermott, Bernard Escudier, et al.
Nature Communications
|
December 21, 2017
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
David Liu, Philip Abbosh, Daniel Keliher, et al.
European Urology Oncology
|
November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial
Fern Anari, John O'Neill, Woonyoung Choi, et al.
The New England Journal of Medicine
|
February 20, 2019
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I Rini, Elizabeth R Plimack, Viktor Stus, et al.
Page
of 21